CAMBRIDGE, Mass., Sept. 18, 2024. Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary...

MONDAY, Sept. 23, 2024 -- Psilocybin, the active ingredient in magic mushrooms, appears to ease depression symptoms at least as well as one of the...

Psilocybin, a psychedelic compound, offers promising relief for depression, improving symptoms and social functioning beyond traditional SSRIs with...

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis Cardiol...

Ideaya Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced...

WEDNESDAY, Sept. 18, 2024 -- The demand for psilocybin-assisted therapy (PSIL-AT) for major depressive disorder (MDD) and treatment-resistant...

Cytovation ASA, a clinical stage oncology company focused on the development of its first─in─class bifunctional immunotherapy CY─101 (CyPep─1)...

Late-stage drug development company Paradigm Biopharmaceuticals has a clear pathway from the FDA for progression of its Phase 3 trial ...

Competitive: ICON Plc: Clinical Trial Manager - Japan, Tokyo Hybrid: Office/Remote ICON plc is a world-leading healthcare intelligence and clinical...